CHD/Prevention News

CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.

CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.

CHICAGO — For adults at high or very high CVD risk, a monthly PCSK9 inhibitor added to maximally tolerated oral lipid-lowering therapy maintained LDL reductions of more than 60% through 72 weeks, with no signals of attenuation.

CHICAGO — The rate of deaths from CVD increased in rural areas and decreased in urban areas of the U.S. from 2010 to 2022, and the difference was especially pronounced amid the COVID-19 pandemic and among younger adults, researchers reported.

Children with normal blood pressure may not need BP screenings as often as current recommendations call for, according to a longitudinal study published in JAMA Pediatrics.

Most lipid-lowering medications lack safety data for pregnant and lactating women, complicating management of hyperlipidemia and hypertriglyceridemia, but data suggest statins can be used for those at high risk for cardiovascular events.

Older Chinese adults with hearing, visual or dual sensory impairment had higher risk for CVD compared with those without sensory impairment, according to a study published in the Journal of the American Heart Association.

Adults who followed a “weekend warrior” physical activity pattern had a similarly lower risk for incident disease compared with those who followed a regular activity pattern, according to study findings published in Circulation.

SAN ANTONIO — Once-daily oral semaglutide conferred more weight loss vs. placebo plus lifestyle intervention and was similar vs. larger oral GLP-1 receptor agonist doses and weekly injectables for efficacy and safety, a speaker reported.

Editor’s Note: This is part three of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .